A carregar...
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradig...
Na minha lista:
| Publicado no: | Ann Transl Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635257/ https://ncbi.nlm.nih.gov/pubmed/29057236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.06.48 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|